Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease
Author:
Affiliation:
1. Royal Manchester Children's Hospital; Oxford Road Manchester UK M13 9WL
2. Academic Medical Hospital (AMC) Amsterdam; Department of Gastroenterology; Meibergdreef 9, C2-113 1105 AZ Amsterdam Netherlands
Publisher
Wiley
Subject
Pharmacology (medical)
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD007351.pub2/fullpdf
Reference21 articles.
1. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease;Sabate;Aliment Pharmacol Ther,2002
2. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease;Bariol;J Gastroenterol Hepatol,2002
3. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease;Bauditz;Gut,2002
4. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007
5. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial;Ehrenpreis;Gastroenterology,1999
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring the Targets and Molecular Mechanisms of Thalidomide in the Treatment of Ulcerative Colitis: Network Pharmacology and Experimental Validation;Current Pharmaceutical Design;2023-09
2. Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents;RSC Advances;2022
3. Targeted protein degradation and regulation with molecular glue: past and recent discoveries;Current Medicinal Chemistry;2021-08-06
4. SnapshotDx Quiz: February 2021;Journal of Investigative Dermatology;2021-02
5. It’s What’s Up Front That Counts—Part Two: Esophageal Crohn’s Disease Complicated by Recurrent Upper Gastrointestinal Bleeding;Digestive Diseases and Sciences;2019-11-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3